BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1656 related articles for article (PubMed ID: 28377466)

  • 21. Additional value of
    van Ramshorst MS; Teixeira SC; Koolen BB; Pengel KE; Gilhuijs KG; Wesseling J; Rodenhuis S; Valdés Olmos RA; Rutgers EJ; Vogel WV; Sonke GS; Vrancken Peeters MT
    Cancer Imaging; 2017 May; 17(1):15. PubMed ID: 28545563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
    Schmitz AMT; Teixeira SC; Pengel KE; Loo CE; Vogel WV; Wesseling J; Rutgers EJT; Valdés Olmos RA; Sonke GS; Rodenhuis S; Vrancken Peeters MJTFD; Gilhuijs KGA
    PLoS One; 2017; 12(5):e0176782. PubMed ID: 28531188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Textural features of
    Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J
    Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of
    Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS
    BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
    Hennessy MA; Leal JP; Huang CY; Solnes LB; Denbow R; Abramson VG; Carey LA; Liu MC; Rimawi M; Specht J; Storniolo AM; Valero V; Vaklavas C; Winer EP; Krop IE; Wolff AC; Cimino-Mathews A; Wahl RL; Stearns V; Connolly RM
    J Nucl Med; 2023 Nov; 64(11):1690-1696. PubMed ID: 37652539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated tumor-to-liver uptake ratio (TLR) from
    Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
    J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
    Lian W; Liu C; Gu B; Zhang J; Lu L; Pan H; Yao Z; Wang M; Song S; Zhang Y; Yang Z
    Nucl Med Commun; 2020 Mar; 41(3):280-287. PubMed ID: 32032193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from
    Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1787-1795. PubMed ID: 28616695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of
    Han S; Choi JY
    Breast Cancer Res; 2020 Oct; 22(1):119. PubMed ID: 33129348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of breast imaging parameters obtained from
    Grapin M; Coutant C; Riedinger JM; Ladoire S; Brunotte F; Cochet A; Humbert O
    Eur J Radiol; 2019 Apr; 113():81-88. PubMed ID: 30927964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
    Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
    Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
    Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
    [No Abstract]   [Full Text] [Related]  

  • 36. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer.
    Hyun SH; Ahn HK; Park YH; Im YH; Kil WH; Lee JE; Nam SJ; Cho EY; Choi JY
    Radiology; 2015 Apr; 275(1):235-44. PubMed ID: 25496075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
    Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
    Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
    Evangelista L; Cervino AR; Ghiotto C; Saibene T; Michieletto S; Fernando B; Orvieto E; Guarneri V; Conte P
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1648-1655. PubMed ID: 26025244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
    Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.